Meeting
2013 ASCO Annual Meeting
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: Data from the Italian cohort of ipilimumab expanded access programme (EAP).
Authors
Paolo Antonio Ascierto
Melanoma Unit, Fondazione Pascale - National Cancer Institute, Naples, Italy
Paolo Antonio Ascierto , Ester Simeone , Vanna Chiarion-Sileni , Paola Queirolo , Michele Del Vecchio , Lorenza Di Guardo , Massimo Guidoboni , Paolo Marchetti , Gian Carlo Antonini Cappellini , Pier Francesco Ferrucci , Francesco Cognetti , Maria Grazia Bernengo , Michele Guida , Riccardo Marconcini , Mario Mandala , Giorgio Parmiani , Gaetana Rinaldi , Massimo Aglietta , Luana Calabro , Michele Maio
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Citation
J Clin Oncol 31, 2013 (suppl; abstr 9035)
DOI
10.1200/jco.2013.31.15_suppl.9035
Abstract #
9035
Poster Bd #
23
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Real-world overall survival in advanced melanoma from the IMAGE study.
First Author: Mark R. Middleton
Poster
2014 ASCO Annual Meeting
Vemurafenib treatment in patients with BRAF-mutated melanoma failing MEK inhibition with trametinib.
First Author: Helen Gogas
Poster
2013 ASCO Annual Meeting
Italian cohort of ipilimumab expanded access programme (EAP): Efficacy, safety, and correlation with mutation status in metastatic melanoma patients.
First Author: Paola Queirolo
Poster
2020 ASCO Virtual Scientific Program
The impact of BRAF mutation status on clinical outcomes with single-agent PD-1 inhibitor versus combination ipilimumab/nivolumab.
First Author: Vincent The-Luc Ma